SCHEMBL9890715

SCHEMBL9890715

CN(C)C(=O)Cc1ccccc1-c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.49
CHRM1 P11229 1/20 0.47
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
SUCNR1 Q9BXA5 3/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43
FFAR4 Q5NUL3 2/20 0.43
FFAR1 O14842 1/20 0.43
NR4A2 P43354 1/20 0.42
PTGS2 P35354 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41
LTB4R2 Q9NPC1 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
F10 P00742 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8720333 0.87 KMT2A (0.51) CHRM1SLC6A4SLC6A3NR4A2LTB4R2
SCHEMBL9890721 0.84 MLNR (0.47) CHRM1SLC6A4SLC6A3PTGDR2FFAR4
SCHEMBL9890717 0.84 CHRM1 (0.65) CHRM1NR4A2
SCHEMBL2393653 0.81 TACR1 (0.47) FFAR4FFAR1
SCHEMBL7598404 0.80 CYP2C19 (0.54) CYP2C19SLC6A4SLC6A3SUCNR1PTGDR2
SCHEMBL3540535 0.80 SUCNR1 (0.56) CYP2C19CHRM1SLC6A4SLC6A3SUCNR1
SCHEMBL6184923 0.79 CYP2C19 (0.64) CYP2C19SLC6A4SLC6A3SUCNR1PTGDR2
SCHEMBL9890714 0.78 CYP2C19 (0.49) CYP2C19CHRM1SLC6A4SLC6A3SUCNR1
SCHEMBL11331947 0.76 SIGMAR1 (0.51) NR4A2NPC1RAB9AALDH1A1
SCHEMBL10058354 0.76 PTGS2 (0.52) CYP2C19SLC6A4SLC6A3SUCNR1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CYP2C19 240/4885CHRM1 340/4885SLC6A4 932/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CYP2C19 240/4885CHRM1 340/4885SLC6A4 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.